Reaction: Rucaparib to 1 product

Reaction
Rucaparib
DB12332
Rucaparib M323 metabolite
DBMET03519
Reaction type
oxidation
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Liao M, Watkins S, Nash E, Isaacson J, Etter J, Beltman J, Fan R, Shen L, Mutlib A, Kemeny V, Papai Z, van Tilburg P, Xiao JJ: Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020 Jun;38(3):765-775. doi: 10.1007/s10637-019-00815-2. Epub 2019 Jun 27. [Article]
  2. FDA Approved Drug Products: RUBRACA (rucaparib) tablets, for oral use (June 2022) [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 2D6Not AvailableNot Availableimplied
Cytochrome P450 1A2Not AvailableNot Availableimplied
Cytochrome P450 3A4Not AvailableNot Availableimplied